Not Signed In -
Naproxen |
Aleve; Anaprox; Anaprox DS; EC-Naprosyn; Naprelan; Naprosyn |
Clinical Trial: A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient with Rheumatoid Arthritis
This study is no longer recruiting patients.
|
Purpose
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
| Condition | Intervention | Phase |
|---|---|---|
| Rheumatoid Arthritis | Drug: MK0966; rofecoxib | Phase IV |
MedlinePlus related topics: Rheumatoid Arthritis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 Mg Once Daily Versus Naproxen Table 500 Mg Twice Daily in the Treatment of Chinese Patient with Rheumatoid Arthritis
Further Study Details:
Study start: February 2004
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Chinese males or females at least 18 years of age with rheumatoid arthritis
Location Information
China
Merck Sharp & Dohme (China) Ltd., Beijing, 100738, China
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_063
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157872
Health Authority: China: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157872
Health Authority: China: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
